Companies › Crystalys Therapeutics
1 active drug program in 4 registered trials: 2 Phase 3, 1 Phase 2, 1 Phase 4; Cardiovascular, Metabolic and endocrine; next expected readout Jul 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Dotinurad Solute carrier family 22 member 12 inhibitor | SLC22A12 | Phase 3 | Gout; Tophaceous Gout; Hyperuricemia or Gout | Jul 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07535034 | Dotinurad | Phase 2 | Gout | Metabolic and endocrine | Jul 2027 |
| NCT06834230 | Dotinurad | Phase 4 | Hyperuricemia or Gout | Cardiovascular | Jul 2027 |
| NCT07089875 | Dotinurad | Phase 3 | Gout | Metabolic and endocrine | Nov 2027 |
| NCT07089888 | Dotinurad | Phase 3 | Tophaceous Gout | Metabolic and endocrine | Dec 2027 |
Lexicon Pharmaceuticals Vincentage Pharma Fresenius Kabi Pulmovant EBI Anti Sepsis
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.